Incyte Corporation
0J9P.L
London Stock Exchange117.34
USD
+1.55
- -
Incyte Corporation
0J9P.L
(London Stock Exchange)
Recent
price
117.34
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Incyte Corporation (NASDAQ: INCY; LSE: 0J9P.L) is a Wilmington, Delaware-based biopharmaceutical company founded in 1991 that discovers, develops, and commercializes proprietary small-molecule drugs and biologics targeting unmet medical needs in hematology, oncology, dermatology, inflammation, and autoimmunity. The company offers a portfolio of approved products including Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor for myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD); Opzelura (ruxolitinib cream), a topical JAK inhibitor for atopic dermatitis and vitiligo; Niktimvo (axatilimab), a monoclonal antibody for chronic GVHD; Pemazyre (pemigatinib), a FGFR inhibitor for certain cholangiocarcinomas and myeloid/lymphoid neoplasms; Monjuvi (tafasitamab), an anti-CD19 monoclonal antibody for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; and others such as Zynyz (retifanlimab), a PD-1 inhibitor for oncology indications. Incyte conducts operations across North America, Europe (with headquarters in Switzerland), Asia-Pacific, and Canada, selling through specialty pharmacies, hospitals, distributors, and wholesalers while advancing a pipeline of late-stage candidates like ruxolitinib XR, povorcitinib for hidradenitis suppurativa, and topical Opzelura expansions. In recent developments, Incyte expanded its partnership with Specialised Therapeutics in June 2025 to distribute axatilimab (Niktimvo) and retifanlimab (Zynyz) in Australia, New Zealand, Singapore, and potentially additional Asia-Pacific markets; reported 20% Q3 2025 revenue growth driven by Jakafi ($791 million), Opzelura, and Niktimvo ($46 million); acquired Escient Pharmaceuticals in April 2024 for $750 million to bolster dermatology assets (despite a subsequent pipeline pause); streamlined early-stage R&D by discontinuing select programs like povorcitinib for urticaria; and relocated its global headquarters to downtown Wilmington, Delaware, in 2025.